John O'Donnell, BS

AUROBAC Therapeutics

Disclosure(s): AUROBAC Therapeutics: employee, Ownership Interest, Stocks/Bonds (Private Company); Innoviva Specialty Therapeutics, Inc: Stocks/Bonds (Public Company)

Poster(s):

• (P-444) Population Pharmacokinetics (PPK) Analysis of Sulbactam-Durlobactam (SUD) to Support Dose Selection for Evaluation in a Clinical Trial in Pediatric Patients with Acinetobacter Baumannii-Calcoaceticus Complex (ABC) Infections
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET